Teva Pharmaceutical Industries (TEVA) said Tuesday it priced its $2.3 billion senior notes offering, upsized from the previously announced $2 billion.
The offering consists Teva Pharmaceutical Finance Netherlands II's 1 billion euros ($1.13 billion) aggregate principal amount of 4.125% euro-denominated senior notes due 2031; Teva Pharmaceutical Finance Netherlands III's $500 million aggregate principal amount of 6% USD-denominated senior notes due 2032; and Teva Pharmaceutical Finance Netherlands IV's $700 million aggregate principal amount of 5.75% USD-denominated senior notes due 2030.
Teva said it will use the proceeds to fund cash tender offers for certain notes maturing in 2026, 2027, 2029, and 2031, and to repay outstanding debt.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.